Skip to main content
. 2023 Oct 29;24(21):15718. doi: 10.3390/ijms242115718

Figure 3.

Figure 3

Efficacy of highly specific sigma receptor ligands on SARS-CoV-2 survival in ACE2-transgenic mice. The ACE2-transgenic mice underwent intranasal challenge with 2.5 × 104 PFU SARS-CoV-2 (strain UF-1) and subsequently received treatment either with the vehicle control (mock-treated), CM398 (sigma-2 receptor-specific ligand), or AZ66 (dual sigma-1/sigma-2 receptor ligand). Two distinct dosing regimens were employed, intraperitoneal (IP) injection either daily or twice daily. The number of animals in the saline-treated group was 8, whereas the treated groups contained 5 animals each. The displayed results capture the survival outcome for each respective treatment.